FutureMeds GmbH

The FutureMeds GmbH site in Offenbach Am Main is running a strong portfolio in cardiovascular diseases and nutritional and metabolic diseases, with studies focused on atherosclerotic cardiovascular disease, hypertension, heart failure, obesity, and hypercholesterolemia. These trials are designed to test new treatments and assess whether they can better reduce cardiovascular risk, improve cholesterol control, and support weight management.

• Testing therapies for atherosclerotic cardiovascular disease and broader high cardiovascular risk
• Studying treatments for heart failure with preserved or mildly reduced ejection fraction linked to obesity
• Evaluating approaches for hypertension, elevated Lp(a), and hyperlipidemia
• Assessing weight-focused care in overweight and obesity populations

Overall, the research aims to improve prevention and treatment options for people with common but serious cardiometabolic conditions.

This research program includes musculoskeletal diseases and pain-related conditions such as osteoarthritis, chronic knee pain, and neuropathic pain. The studies are mainly evaluating whether new therapies can ease long-term pain, improve daily function, and offer better symptom control for people living with joint and nerve-related disorders.

• Investigating treatment options for osteoarthritis of the knee
• Exploring therapies for chronic pain and pain associated with diabetic peripheral neuropathy
• Assessing relief strategies for distal sensory polyneuropathy
• Measuring changes in pain and mobility-related outcomes

These studies reflect a practical focus on reducing persistent pain and improving quality of life for patients with chronic movement and nerve disorders.

The site is also active in respiratory tract diseases and virus diseases, with trials in chronic obstructive pulmonary disease and influenza. This work is aimed at evaluating new treatments and vaccines that may improve respiratory health, lower illness burden, and strengthen protection against seasonal viral infections.

• Studying treatment approaches for COPD and related cardiopulmonary outcomes
• Testing a vaccine candidate for influenza prevention
• Assessing safety and immune response in adult participants
• Supporting better control of chronic breathing problems and infectious disease risk

At FutureMeds GmbH, these trials connect long-term respiratory care with prevention-focused infectious disease research.

Another important area of activity covers nervous system diseases and psychiatry and psychology, including cognitive impairment associated with post-COVID-19 syndrome and major depressive disorder. The studies are designed to evaluate whether new or repurposed therapies can improve cognitive performance, reduce depressive symptoms, and support mental well-being.

• Examining treatment options for post-COVID cognitive impairment
• Evaluating therapies for mild to moderate major depressive disorder
• Measuring changes in memory, attention, and mood-related outcomes
• Exploring better symptom relief for people affected by persistent neurological and emotional conditions

These trials highlight a patient-centered effort to address both brain health and emotional health in everyday clinical care.

The site is conducting research in skin and connective tissue diseases and immune-mediated disorders, including chronic spontaneous urticaria and related inflammatory conditions. The main purpose of these trials is to determine whether new therapies can better control symptoms, reduce flare-ups, and improve comfort for people living with ongoing allergic or inflammatory disease.

• Investigating treatment options for moderate to severe chronic spontaneous urticaria
• Assessing symptom control in persistent inflammatory skin conditions
• Evaluating safety and effectiveness of new immune-targeted therapies
• Studying outcomes that matter most to patients, such as itch relief and daily functioning

This area adds an important immunology-focused dimension to the broader clinical trial portfolio at the Offenbach Am Main site.

Several studies at FutureMeds GmbH address the overlap between chronic kidney disease, type 2 diabetes, hypertension, and cardiovascular complications. The research is aimed at testing whether new treatment combinations can better protect kidney function, lower major cardiovascular events, and improve overall outcomes in people with complex metabolic disease.

• Studying therapies for chronic kidney disease with high blood pressure
• Evaluating treatment approaches in type 2 diabetes with established cardiovascular disease
• Measuring protection against kidney decline and heart-related events
• Exploring therapies that may improve long-term cardiometabolic stability

These trials reflect a growing focus on integrated care for patients whose kidney, metabolic, and heart conditions are closely linked.

The site also contributes to behavioral disciplines and activities through studies in alcohol use disorder. This research is centered on evaluating whether new treatment options can help reduce alcohol consumption and support sustained improvement in people with moderate to severe dependence.

• Testing interventions for alcohol use disorder
• Assessing reduction in alcohol consumption over time
• Exploring maintenance of treatment benefit after initial response
• Supporting better care options for behavioral health needs

It adds an important addiction medicine component to the site's broader mix of cardiometabolic, respiratory, and neurological research.